- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02650674
Determination of the Glycaemic Index and Insulinaemic Index Values of Five Cereal Products
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
New South Wales
-
Sydney, New South Wales, Australie, 2006
- University of Sydney
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Aged between 18-45 years.
- Non-smoker.
- BMI values: between 19-25 kg/m2 (bounds included) for Caucasian subjects and between 19-23 kg/m2 (bounds included) for Asian subjects (WHO expert consultation).
- Ethnicity: Caucasian subjects will have both parents from Caucasian ancestry. Asian subjects will have both parents from Asian country and will be born in an Asian country. Asian countries are: Brunei Darussalam, Cambodia, China, Dem. People's Republic of Korea, Hong Kong SAR (China), Indonesia, Japan, Lao People's Democratic Republic, Macao SAR (China), Malaysia, Mongolia, Myanmar, Philippines, Republic of Korea, Singapore, Taiwan, Thailand, Viet Nam.
- Sex ratio: Around half of the subjects should be male and half of the subjects should be female within each study group. A plus or minus 1 subject tolerance will be accepted.
- Healthy subjects with:
Normal glucose tolerance Normal laboratory values for various measures of metabolic health (full blood count, gamma-GT, AST, ALT, glucose, TAGs, total cholesterol, HDL-cholesterol, LDL-cholesterol); Normal systolic blood pressure (100-150 mmHg); Normal diastolic blood pressure (60-90 mmHg); Normal resting heart rate (50-90 beats per minutes after 3 minutes rest).
- Stable dietary habits; normal eating patterns; no history of eating disorders or strict dieting.
- Moderate level of physical activity (from basic daily activity to a high level of physical activity (regular physical activity at least 3 times per week))
- Able to fast for at least 10 hours the night before each test session.
- Able to refrain from eating legumes and drinking alcohol the day before each test session.
- Subject covered by social security or covered by a similar system
- Subject not taking any treatment for anorexia, weight loss, or any form of treatment likely to interfere with metabolism or dietary habits
- Subject having given written consent to take part in the study.
Exclusion Criteria:
- Following a restrictive diet.
- Family history of Diabetes Mellitus or obesity
- Suffering from any clinical, physical or mental illness.
- Suffering from any food allergies or hypersensitivities (wheat, milk, egg, nuts, etc).
- Taking any regular prescription medication at the time of inclusion (except regular oral contraception medication)
- Female who is pregnant (positive test results), lactating, planning pregnancy or not using acceptable contraceptive.
- Females who consistently suffer from premenstrual tension and marked changes in appetite during their menstrual cycle.
- Subject having taken part in another clinical trial within the last week.
- Subject currently taking part in another clinical trial or being in the exclusion period of another clinical trial.
- Subject undergoing general anaesthesia in the month prior to inclusion.
- Subject in a situation which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Product A: NP-0148
Cereal product belVita Milk & Cereals - High in SDS
|
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
|
|
Expérimental: Product B: NP-0149
Cereal product belVita Honey & Nuts - High in SDS
|
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
|
|
Expérimental: Product C: NP-0150
Cereal product belVita Mixed Berry - High in SDS
|
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
|
|
Expérimental: Product D: NP-0151
Cereal product Kellogg's Corn Flakes - Low in SDS - Low in fat
|
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
|
|
Expérimental: Product E: NP-0152
Cereal product Kellogg's Trésor Duo Choco - Low in SDS
|
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
|
|
Expérimental: Glucose reference
Glucose solution performed on three occasions
|
Glucose solution providing 50 g of available carbohydrates in 250 ml of water.
This will be performed 3 times
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Glycaemic index values of five cereal products
Délai: 2 hours after food consumption
|
Determination of GI in both Caucasian and Asian subjects
|
2 hours after food consumption
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Glycaemic response assessed by the glycemic index (GI) values of five cereal products
Délai: 2 hours after food consumption
|
Determination of GI in the global population
|
2 hours after food consumption
|
|
Glycaemic response assessed by the postprandial changes in glycaemia over 2 hours (iAUC0-120) after consumption of the test products
Délai: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Glycaemic response assessed by the kinetic of glycemia over the 120 minutes
Délai: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Glycaemic response assessed by the peak value of glycemia
Délai: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Glycaemic response assessed by the delta value between baseline and peak values of glycemia
Délai: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Insulinaemic response assessed by the insulinemic index (II) values of five cereal products
Délai: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Insulinaemic response assessed by the postprandial changes in insulinemia over 2 hours (iAUC0-120) after consumption of the test products
Délai: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Insulinaemic response assessed by the kinetic of insulinemia over the 120 minutes
Délai: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Insulinaemic response assessed by the peak value of insulinemia
Délai: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Insulinaemic response assessed by the delta value between baseline and peak values of insulinemia
Délai: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Insulin / glucose ratio (II/GI) evaluation of five cereal products
Délai: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Postprandial changes in insulin / glucose over 2 hours (iAUC0-120) after consumption of the test products
Délai: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Kinetic of insulin / glucose over the 120 minutes
Délai: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Peak value of insulin / glucose ratio
Délai: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Delta peak value between baseline and peak values of insulin / glucose ratio
Délai: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Jennie Brand Miller, University of Sydney
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- KBE043
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .